Patents by Inventor Kevin A. Goncalves
Kevin A. Goncalves has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230330185Abstract: The invention relates to the in vivo transduction of hematopoietic stem and progenitor cells (HSPCs) in a subject, such as a human subject, and to the treatment of subjects suffering from various pathologies, such as blood diseases, metabolic disorders, cancers, and autoimmune diseases, among others.Type: ApplicationFiled: April 27, 2021Publication date: October 19, 2023Inventors: Anthony Boitano, Kevin A. Goncalves, Dwight Morrow, Andre Lieber, Hans-Peter Kiem, Michael P. Cooke
-
Publication number: 20230130646Abstract: Described herein are compositions and methods useful for mobilizing populations of hematopoietic stem and progenitor cells within a subject, as well as for determining whether samples of mobilized cells are suitable for release for ex vivo expansion and/or therapeutic use. In accordance with the composition and methods described herein, mobilized hematopoietic stem and progenitor cells can be withdrawn from a donor and administered to a patient for the treatment of various disorders, including hematopoietic diseases, metabolic disorders, cancers, and autoimmune diseases, among others.Type: ApplicationFiled: May 12, 2022Publication date: April 27, 2023Inventors: Dwight Morrow, Patrick C. Falahee, Anthony Boitano, Michael P. Cooke, Kevin A. Goncalves
-
Publication number: 20220401481Abstract: The invention provides compositions and methods useful for mobilizing populations of hematopoietic stem and progenitor cells within a donor, as well as for determining whether samples of mobilized cells are suitable for release for ex vivo expansion and/or therapeutic use. In accordance with the compositions and methods described herein, mobilized hematopoietic stem and progenitor cells can be withdrawn from a donor and administered to a patient for the treatment of various stem cell disorders, including hematopoietic diseases, metabolic disorders, cancers, and autoimmune diseases, among others.Type: ApplicationFiled: October 30, 2020Publication date: December 22, 2022Inventors: Anthony Boitano, Michael P. Cooke, John C. Davis, Patrick C. Falahee, Kevin A. Goncalves, Sharon Hyzy, Dwight Morrow, Jason Neale, Glen Raffel, William Savage, Veit Schmelmer
-
Publication number: 20220096559Abstract: The invention provides compositions and methods useful for mobilizing populations of hematopoietic stem and progenitor cells within a donor, as well as for determining whether samples of mobilized cells are suitable for release for ex vivo expansion and/or therapeutic use. In accordance with the compositions and methods described herein, mobilized hematopoietic stem and progenitor cells can be withdrawn from a donor and administered to a patient for the treatment of various stem cell disorders, including hematopoietic diseases, metabolic disorders, cancers, and autoimmune diseases, among others. In certain embodiments, the compositions and methods described herein lead to the mobilization of a population of CD34dim cells that have immunosuppressive effects and that can reduce the incidence of graft vs. host disease.Type: ApplicationFiled: May 7, 2021Publication date: March 31, 2022Inventors: Dwight Morrow, Patrick C. Falahee, Anthony Boitano, Michael P. Cooke, Kevin A. Goncalves
-
Patent number: 11260079Abstract: The invention provides compositions and methods useful for mobilizing populations of hematopoietic stem and progenitor cells within a donor, as well as for determining whether samples of mobilized cells are suitable for release for ex vivo expansion and/or therapeutic use. In accordance with the compositions and methods described herein, mobilized hematopoietic stem and progenitor cells can be withdrawn from a donor and administered to a patient for the treatment of various stem cell disorders, including hematopoietic diseases, metabolic disorders, cancers, and autoimmune diseases, among others. In certain embodiments, the compositions and methods described herein lead to the mobilization of a population of CD34dim cells that have immunosuppressive effects and that can reduce the incidence of graft vs. host disease.Type: GrantFiled: March 13, 2019Date of Patent: March 1, 2022Assignee: Magenta Therapeutics, Inc.Inventors: Dwight Morrow, Patrick C. Falahee, Anthony Boitano, Michael P. Cooke, Kevin A. Goncalves
-
Publication number: 20210220408Abstract: The disclosure relates to aryl hydrocarbon receptor antagonists as well as methods of modulating aryl hydrocarbon receptor activity and expanding hematopoietic stem cells by culturing hematopoietic stem or progenitor cells in the presence of these agents. Additionally, the disclosure provides methods of treating various pathologies, such as cancer, by administration of these aryl hydrocarbon receptor antagonists. Additionally, the disclosure provides methods of treating various pathologies in a patient by administration of expanded hematopoietic stem cells. The disclosure further provides kits containing aryl hydrocarbon receptor antagonists that can be used for the expansion of hematopoietic stem cells. The disclosure further relates to pharmaceutical compositions comprising the compounds and methods of treating or preventing a disease in which aryl hydrocarbon receptor plays a role.Type: ApplicationFiled: September 4, 2019Publication date: July 22, 2021Inventors: Anthony BOITANO, Michael COOKE, Kevin A. GONCALVES, Megan HOBAN
-
Publication number: 20210179625Abstract: The disclosure relates to aryl hydrocarbon receptor antagonists, such as substituted imidazopyridines and imidazopyrazines, as well as methods of expanding hematopoietic stem cells by culturing hematopoietic stem or progenitor cells in the presence of these agents. Additionally, the disclosure provides methods of treating various pathologies in a patient by administration of expanded hematopoietic stem cells. The disclosure further provides methods of synthesizing aryl hydrocarbon receptor antagonists, such as substituted imidazopyridines and imidazopyrazines, as well as kits containing aryl hydrocarbon receptor antagonists that can be used for the expansion of hematopoietic stem cells.Type: ApplicationFiled: December 18, 2020Publication date: June 17, 2021Inventors: Arthur Glenn ROMERO, Kevin A. GONCALVES
-
Publication number: 20200338132Abstract: Provided herein are compositions and methods useful for the expansion of hematopoietic stem and progenitor cells. In accordance with the composition and methods described herein, hematopoietic stem and progenitor cells may be expanded, for instance, by treatment ex vivo with an aryl hydrocarbon receptor antagonist, and may be infused into a patient, such as a patient in need of hematopoietic stem cell transplant therapy. Thus, provided herein are methods for the treatment of various related disorders, including inherited metabolic disorders, among others.Type: ApplicationFiled: January 3, 2019Publication date: October 29, 2020Inventors: Anthony BOITANO, Kevin A. GONCALVES, Michael COOKE
-
Publication number: 20200123161Abstract: The disclosure relates to aryl hydrocarbon receptor antagonists, such as substituted imidazopyridines and imidazopyrazines, as well as methods of expanding hematopoietic stem cells by culturing hematopoietic stem or progenitor cells in the presence of these agents. Additionally, the disclosure provides methods of treating various pathologies in a patient by administration of expanded hematopoietic stem cells. The disclosure further provides methods of synthesizing aryl hydrocarbon receptor antagonists, such as substituted imidazopyridines and imidazopyrazines, as well as kits containing aryl hydrocarbon receptor antagonists that can be used for the expansion of hematopoietic stem cells.Type: ApplicationFiled: September 13, 2019Publication date: April 23, 2020Inventors: Arthur Glenn ROMERO, Kevin A. GONCALVES
-
Publication number: 20190336536Abstract: The invention provides compositions and methods useful for mobilizing populations of hematopoietic stem and progenitor cells within a donor, as well as for determining whether samples of mobilized cells are suitable for release for ex vivo expansion and/or therapeutic use. In accordance with the compositions and methods described herein, mobilized hematopoietic stem and progenitor cells can be withdrawn from a donor and administered to a patient for the treatment of various stem cell disorders, including hematopoietic diseases, metabolic disorders, cancers, and autoimmune diseases, among others. In certain embodiments, the compositions and methods described herein lead to the mobilization of a population of CD34dim cells that have immunosuppressive effects and that can reduce the incidence of graft vs. host disease.Type: ApplicationFiled: December 6, 2018Publication date: November 7, 2019Inventors: Dwight Morrow, Patrick C. Falahee, Anthony Boitano, Michael P. Cooke, Kevin A. Goncalves
-
Publication number: 20190314407Abstract: Provided herein are compositions and methods useful for the expansion of hematopoietic stem and progenitor cells, such as those that have been genetically modified, for instance, to express a heterologous transgene. In accordance with the composition and methods described herein, hematopoietic stem and progenitor cells may be genetically modified, for example, to express transgenes encoding therapeutic proteins. Genetically modified hematopoietic stem and progenitor cells may be expanded, for instance, by treatment ex vivo with an aryl hydrocarbon receptor antagonist, and may be infused into a patient, such as a patient in need of hematopoietic stem cell transplant therapy. Thus, provided herein are methods for the treatment of various stem cell disorders, including hematopoietic diseases, metabolic disorders, cancers, and autoimmune diseases, among others.Type: ApplicationFiled: October 31, 2018Publication date: October 17, 2019Inventors: Anthony BOITANO, Michael COOKE, Kevin A. GONCALVES
-
Publication number: 20190269735Abstract: The invention provides compositions and methods useful for mobilizing populations of hematopoietic stem and progenitor cells within a donor, as well as for determining whether samples of mobilized cells are suitable for release for ex vivo expansion and/or therapeutic use. In accordance with the compositions and methods described herein, mobilized hematopoietic stem and progenitor cells can be withdrawn from a donor and administered to a patient for the treatment of various stem cell disorders, including hematopoietic diseases, metabolic disorders, cancers, and autoimmune diseases, among others. In certain embodiments, the compositions and methods described herein lead to the mobilization of a population of CD34dim cells that have immunosuppressive effects and that can reduce the incidence of graft vs. host disease.Type: ApplicationFiled: March 13, 2019Publication date: September 5, 2019Inventors: DWIGHT MORROW, PATRICK C. FALAHEE, ANTHONY BOITANO, MICHAEL P. COOKE, KEVIN A. GONCALVES
-
Publication number: 20190167726Abstract: Described herein are compositions and methods useful for mobilizing populations of hematopoietic stem and progenitor cells within a subject, as well as for determining whether samples of mobilized cells are suitable for release for ex vivo expansion and/or therapeutic use. In accordance with the composition and methods described herein, mobilized hematopoietic stem and progenitor cells can be withdrawn from a donor and administered to a patient for the treatment of various disorders, including hematopoietic diseases, metabolic disorders, cancers, and autoimmune diseases, among others.Type: ApplicationFiled: August 13, 2018Publication date: June 6, 2019Inventors: Dwight Morrow, Patrick C. Falahee, Anthony Boitano, Michael P. Cooke, Kevin A. Goncalves
-
Publication number: 20190000885Abstract: Aspects of the technology disclosed herein generally (and in part) relates to use of Angiogenin (ANG) for increasing hematopoietic reconstitution of in vivo hematopoietic cells and transplanted hematopoietic cells. Provided herein are methods and compositions useful in treatment of diseases characterized by decreased levels of hematopoietic cells, decreased levels of hematopoietic reconstitution, blood cell deficiency and prevention and treatment of radiation injury. One aspect relates to angiogenin treated hematopoietic cell compositions and methods of their use in stem cell transplantation. Treatment of hematopoietic cells with angiogenin enhances quiescence and reduces proliferative capacity of primitive hematopoietic stem cells while increasing proliferation of myeloid restricted progenitor cells. Another aspect relates to use of ANG in prophylactic and therapeutic treatment methods for radiation injury.Type: ApplicationFiled: November 29, 2016Publication date: January 3, 2019Applicants: THE GENERAL HOSPITAL CORPORATION, TUFTS MEDICAL CENTER, INC., TRUSTEES OF TUFTS COLLEGE, PRESIDENT AND FELLOWS OF HARVARD COLLEGEInventors: David SCADDEN, Peter KHARCHENKO, Lev SILBERSTEIN, Guo-fu HU, Kevin GONCALVES
-
Publication number: 20180298013Abstract: The disclosure relates to aryl hydrocarbon receptor antagonists, such as substituted imidazopyridines and imidazopyrazines, as well as methods of expanding hematopoietic stem cells by culturing hematopoietic stem or progenitor cells in the presence of these agents. Additionally, the disclosure provides methods of treating various pathologies in a patient by administration of expanded hematopoietic stem cells. The disclosure further provides methods of synthesizing aryl hydrocarbon receptor antagonists, such as substituted imidazopyridines and imidazopyrazines, as well as kits containing aryl hydrocarbon receptor antagonists that can be used for the expansion of hematopoietic stem cells.Type: ApplicationFiled: April 12, 2018Publication date: October 18, 2018Inventors: Arthur Glenn ROMERO, Kevin A. GONCALVES
-
Patent number: 10058573Abstract: Described herein are compositions and methods useful for mobilizing populations of hematopoietic stem and progenitor cells within a subject, as well as for determining whether samples of mobilized cells are suitable for release for ex vivo expansion and/or therapeutic use. In accordance with the composition and methods described herein, mobilized hematopoietic stem and progenitor cells can be withdrawn from a donor and administered to a patient for the treatment of various disorders, including hematopoietic diseases, metabolic disorders, cancers, and autoimmune diseases, among others.Type: GrantFiled: December 6, 2017Date of Patent: August 28, 2018Assignee: Magenta Therapeutics, Inc.Inventors: Dwight Morrow, Patrick C. Falahee, Anthony Boitano, Michael P. Cooke, Kevin A. Goncalves